Please assess the completion status of the following clinical trial:

Trial Title: Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytologically or pathologically confirmed colorectal adenocarcinoma~  * Advanced or metastatic disease~* Refractory to ≥ 1 line of prior therapy~  * Not amenable to potentially curative surgical resection~* Mutations in the PI3K gene in tumor tissue~* Tumor tissue available for genetic testing OR willing to undergo baseline tumor biopsy~  * Tumor amenable to sequential biopsies~ * Willing to undergo 2 sequential tumor biopsies, and 2 sequential skin biopsies~* Measurable lesion with ≥ 1 diameter ≥ 2 cm by conventional CT scan (1 cm by spiral CT scan) in a nonirradiated area~* No known brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%~* Life expectancy \> 12 weeks~* WBC ≥ 3,000/mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal (ULN)~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* Cholesterol and triglycerides ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus~* No uncontrolled intercurrent illness, including, but not limited to, any of the following:~  * Hypertension~ * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness or social situation that would preclude study compliance~* No evidence of bleeding diathesis~* Able to swallow tablets~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered~* No prior targeted therapy against mTOR~* No other concurrent investigational agents~* No concurrent therapeutic anticoagulation~  * Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial access devices allowed provided the requirements for PT, INR or PTT are met.~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent anticancer therapy, including chemotherapy, hormonal therapy, immunotherapy, alternative therapy, or radiotherapy~* No concurrent live vaccination

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).